Skip to content
Rapaflo, Urorec(silodosin)
Rapaflo, Silodyx, Urorec (silodosin) is a small molecule pharmaceutical. Silodosin was first approved as Rapaflo on 2008-10-08. It is used to treat prostatic hyperplasia in the USA. It has been approved in Europe to treat prostatic hyperplasia. The pharmaceutical is active against alpha-1A adrenergic receptor. In addition, it is known to target alpha-1B adrenergic receptor and alpha-1D adrenergic receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
Trade Name
FDA
EMA
Rapaflo (generic drugs available since 2017-03-31)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Silodosin
Tradename
Company
Number
Date
Products
RAPAFLOAllerganN-022206 RX2008-10-08
2 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
rapafloNew Drug Application2020-12-15
silodosinANDA2023-01-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
prostatic hyperplasiaEFO_0000284D011470N40
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G04: Urologicals
— G04C: Drugs used in benign prostatic hypertrophy
— G04CA: Alpha-adrenoreceptor antagonists, benign prostatic hypertrophy
— G04CA04: Silodosin
HCPCS
No data
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic hyperplasiaD011470EFO_0000284N40—246—12
NocturiaD053158R35.1—1—1—2
Ureteral calculiD014514—1—1—2
UreterolithiasisD053039EFO_1001228N20.1———1—1
Neurogenic urinary bladderD001750HP_0000011N31———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Kidney calculiD007669EFO_0004253N20.0—12——3
Urinary calculiD014545N20.9—11——2
Prostatic neoplasmsD011471C61——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Premature ejaculationD061686HP_0012876F52.4—1———1
UrolithiasisD052878N20-N23—1———1
ProstatitisD011472EFO_0003830N41—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSILODOSIN
INNsilodosin
Description
Silodosin is an indolecarboxamide.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F
Identifiers
PDB—
CAS-ID160970-54-7
RxCUI720825
ChEMBL IDCHEMBL24778
ChEBI ID—
PubChem CID5312125
DrugBankDB06207
UNII IDCUZ39LUY82 (ChemIDplus, GSRS)
Target
Agency Approved
ADRA1A
ADRA1A
Organism
Homo sapiens
Gene name
ADRA1A
Gene synonyms
ADRA1C
NCBI Gene ID
148
Protein name
alpha-1A adrenergic receptor
Protein synonyms
Alpha-1A adrenoceptor, Alpha-1A adrenoreceptor, Alpha-1C adrenergic receptor, Alpha-adrenergic receptor 1c, G protein coupled receptor
Uniprot ID
Q9UD67
Mouse ortholog
Adra1a (11549)
alpha-1A adrenergic receptor (Q8BV77)
Alternate
ADRA1B
ADRA1B
ADRA1D
ADRA1D
Organism
Homo sapiens
Gene name
ADRA1B
Gene synonyms
NCBI Gene ID
147
Protein name
alpha-1B adrenergic receptor
Protein synonyms
adrenergic, alpha-1B-, receptor, Alpha-1B adrenoceptor, Alpha-1B adrenoreceptor
Uniprot ID
P35368
Mouse ortholog
Adra1b (11548)
alpha-1B adrenergic receptor (P97717)
Variants
Clinical Variant
No data
Financial
Rapaflo - Allergan
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Rapaflo - Warner Chilcott
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 814 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
52,207 adverse events reported
View more details